Cerium Pharmaceuticals is dedicated to creating efficacious therapies for patients with kidney diseases. Cerium is currently focused on developing the first drug approved for a very rare kidney disease called Primary Membranous Nephropathy (PMN). There are approximately 75,000 PMN patients in the US and approximately 3,000 newly diagnosed PMN patients per year.
Cerium does not shy away from challenging development projects, such as medicines targeting pediatric indications and complex biologic agents. In addition, we seek to make our medicines available globally with the help of “Orphan Drug” legislation programs and “Named Patient” access programs, which are increasingly available around the world.